Answers are grounded in this paper and cite their sources.
Examines the impact of combined lifestyle interventions and medications on obesity-related outcomes, suggesting advanced strategies for treatment.
Obesity arises from the complex interplay between genetic and epigenetic factors, with developmental programming shaping adipose fate, energy homeostasis, and treatment responses later in life. Findings from the developmental origins of health and disease (DOHaD) framework reveal that prenatal factors—such as maternal nutrition, adiposity, hyperglycemia, smoking, and stress—and early exposures imprint dynamic epigenetic marks—DNA methylation, histone modifications, and noncoding RNAs—on key tissues (adipose and hypothalamic circuits), which are associated with both childhood and adult adiposity. These marks contribute to an “epigenetic memory” that exhibits a graded decay model rather than absolute permanence, yet persists even after weight loss, limiting full reversibility of the obese phenotype. This phenomenon is supported by transcriptional and epigenomic profiles of human and mouse adipose tissue following weight loss. In obesity, adipose niche remodeling involves chronic inflammation, fibrosis, and macrophage–fibroblast interactions within “crown-like” structures, with OSM–MINCLE circuits modulating fibrosis. In prevention and therapy, combining lifestyle interventions with dual- or selective-incretin-based drugs results in significant weight loss and improves body composition and muscle function. Beyond classical metabolic targets, several anti-obesity drugs—including metformin, thiazolidinediones, GLP-1 agonists, SGLT2 inhibitors, and nutraceuticals such as resveratrol—also exert epigenetic remodeling effects in liver, muscle, and adipose tissue, although clinical evidence for some nutraceuticals remains limited by bioavailability. Integrating epigenetic biomarkers with critical developmental windows, together with digital health and personalized medicine, could optimize risk stratification and refine our understanding of obesity as a modifiable, yet path-dependent biological condition.
No takes yet. Share an insight, caveat, or question.
Ferder et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: